Eisai
Also known as: Clinical Research Center, Eisai, Co., Ltd | Drug Fostering and evolution Coodination Department, Corporate Regulattory Compliance, Safety and Quality Assurance Headquaters, Eisai Co., Ltd., Japan | Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd. | Drug Fostering and Evolution Coordination Department, Corporate Regulatory Compliance, Safety and Quality Assurance Headquarters, Eisai Co., Ltd. | Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd. | Drug Fostering and Evolution Cordination Department, Eisai Co., Ltd. | Eisai Asia Regional Services Ltd. | Eisai China Inc. | Eisai Co., Ltd. | Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center | Eisai Co., Ltd - Development Clinical Research Dept., Clinical Research Center | Eisai Company Lmited | Eisai Farmaceutica, S.A. | EISAI Farmaceutica S.A. Head of Medical Department | Eisai France | Eisai Global Clinical Development | Eisai Global Study Director | Eisai GmbH | Eisai GmbH, Frankfurt, Germany | Eisai Inc. | EISAI INC | Eisai, Incorporated | Eisai Korea | Eisai Korea Inc. | Eisai Limited | Eisai Limted | EISAI MEDCL RES | Eisai Medical Research (formerly MGI Pharma Inc.) | Eisai Medical Services | Eisai/Morphotek | Eisai Pharmaceuticals India Private limited | Eisai Pharmaceuticals India Pvt. Ltd | Eisai Research Institute | Eisai Taiwan | Frontier Product Creation Unit, Eisai Product Creation Systems | General Manager - Medical and Regulatory Affairs, Eisai Pharmaceuticals India Private Limited | General Manager Medical & Regulatory Affairs, Eisai Pharmaceuticals India Private Limited, Mumbai, MS, India | H3 Biomedicine Inc. | JAC PCU Eisai Co., Ltd. | JAC PCU. EPCS, Eisai Co., Ltd. | Japan/Asia Clinical Research Product Creation Unit | Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd. | Japan/Asia Clinical Research Product Creation Unit, Japan Clinical Development, Japan Clinical Development Section | Japan Clinical Pharmacology, Eisai Co., Ltd. | KAN Clinical Development Section, JAPAN/ASIA Clinical Research Product Creation Unit, Eisai Product Creation System | Medical Affairs Department , Eisai Taiwan Inc. | Medical Affairs, Eisai, Inc | Medical Department, Eisai Korea Inc. | Neuroscience Cliical Development Section, Japan /Asia Clinical Research PCU | Neuroscience Clinical Development Section. JAC PCU | Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd. | Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd. | Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd. | Neurosciences Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System. | New Drug Development Department, Eisai Company Limited | New Product Development, Clinical Research Center, Eisai Co., Ltd. | Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd. | Oncology Clinical Development Section. JAC PCU., Eisai, Co., Ltd | Oncology Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System | Post -marketing Clinical Research Department, Clinical Research Center - Eisai Company Limited
Highest phase reached
Phase 4
First clinical trial
Jun 1, 1995First marketed drug
Dec 26, 1990First NDA
Nov 25, 1996Last known activity
Dec 31, 2025
Timeline
1940s
- Jan 1, 1944
Sakuragaoka Laboratory Co, Ltd— Acquired
1950s
- Jan 1, 1955
Eisai— Founded
- Jan 1, 1955
Nihon Eisai— Acquired
1990s
- Feb 5, 1999
denileukin diftitox— NDA Secondary Org
2000s
- Apr 19, 2007
Morphotek— Acquired
- Jan 28, 2008
MGI Pharma— Acquired
2010s
- Jan 6, 2010
AkaRx— Acquired
- Jan 1, 2014
Sarepta Therapeutics— Acquired By
- Dec 4, 2015
Liaoning TianYi Biological Pharmaceutical Co., Ltd.— Acquired
- Dec 20, 2019
lemborexant— Marketing Organization
- Dec 20, 2019
lemborexant— NDA Organization
Drugs by trial phase (216 distinct, 731 trials)
Phase 4 (39 own, 1 via acquisition)
Phase 3 (52 own, 8 via acquisition)
Phase 2 (64 own, 3 via acquisition)
Phase 1 (44 own, 3 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Coronary Syndrome
- Acute Disease
- Adenocarcinoma
- Adenocarcinoma, Follicular
- Adenocarcinoma of Lung
- Alzheimer Disease
- Amnesia
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Anemia, Sickle Cell
- Apnea
- Arthritis
- Arthritis, Juvenile
- Arthritis, Rheumatoid
- Asthma
- Back Pain
- Behcet Syndrome
- Biliary Tract Neoplasms
- Binge-Eating Disorder
- Blast Crisis
- Bone Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Breast Neoplasms, Male
- Bulimia
- CADASIL
- Carcinoma
- Carcinoma, Adenoid Cystic
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Papillary
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Carpal Tunnel Syndrome
- Cartilage Diseases
- Central Nervous System Neoplasms
- Cerebral Infarction
- Cerebrovascular Disorders
- Cervical Intraepithelial Neoplasia
- Chagas Disease
- Cholangiocarcinoma
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colonic Polyps
- Colorectal Neoplasms
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Dementia
- Dementia, Vascular
- Dermatitis
- Dermatitis, Atopic
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Disease
- Disease Progression
- Dizziness
- Down Syndrome
- Duodenal Ulcer
- Dyskinesias
- Dyspepsia
- Dystonia
- Eczema
- Embolism
- Endometrial Neoplasms
- Epilepsies, Myoclonic
- Epilepsies, Partial
- Epilepsy
- Epilepsy, Complex Partial
- Epilepsy, Generalized
- Epilepsy, Reflex
- Epileptic Syndromes
- Erectile Dysfunction
- Esophageal Neoplasms
- Esophagitis
- Esophagitis, Peptic
- Essential Hypertension
- Eye Neoplasms
- Fallopian Tube Neoplasms
- Feeding and Eating Disorders
- Fibromyalgia
- Gastritis
- Gastroesophageal Reflux
- Gastrointestinal Hemorrhage
- Genital Neoplasms, Female
- Genital Neoplasms, Male
- Glioblastoma
- Glioma
- Gliosarcoma
- Headache
- Heartburn
- Hemangioendothelioma
- Hemangioendothelioma, Epithelioid
- Hemangiosarcoma
Marketed drugs (14)
Subsidiaries (6 direct, 8 total across the full acquisition tree)
Recent trials (50)
- NCT03778424Lead sponsorN/A—
- NCT04457687Lead sponsorN/A—
- NCT03533361Lead sponsorN/A—
- NCT07308236Lead sponsorPhase 1Dec 31, 2025
- NCT06964113Lead sponsorPhase 4Jun 11, 2025
- NCT06913907CollaboratorPhase 4Apr 10, 2025
- NCT06854042Lead sponsorPhase 1Feb 26, 2025
- NCT06648681CollaboratorPhase 2Nov 1, 2024
- NCT06625242Lead sponsorPhase 4Oct 15, 2024
- NCT06602258Lead sponsorPhase 2Sep 30, 2024
- NCT06481488Lead sponsorPhase 1Jun 25, 2024
- NCT06462404Lead sponsorPhase 1Jun 20, 2024
- NCT06384573CollaboratorPhase 3Jun 10, 2024
- NCT06188559Lead sponsorPhase 2Apr 10, 2024
- NCT06068153CollaboratorPhase 2Mar 31, 2024
Details
- Founded
- Saitama, JP Jan 1, 1955
- First NDA
- Nov 25, 1996
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Priority review